Experimental treatments brings hope to ALS patients

CBS Saturday Morning reports on an experimental treatment for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, that is offering encouragement to patients battling the progressive neurodegenerative condition. ALS attacks nerve cells in the brain and spinal cord, gradually paralyzing patients and typically proving fatal within two to five years of diagnosis. The emergence of new treatment options represents a significant development for a disease that has historically had limited therapeutic options and no cure. The segment examines how this experimental approach is affecting patient outcomes and what it may mean for the broader ALS community moving forward.